Sanofi (ADR)
Develops immunology-focused medicines and vaccines across a broad international footprint.
Something off on this page? Send us feedback.
Profile
Develops prescription medicines and vaccines across immunology, rare diseases, neurology and oncology, with Dupixent and vaccines central to current execution. Consumer health now sits outside operational control, leaving a single Biopharma segment whose international business depends on clinical development, regulatory approval, manufacturing quality and product safety.
Develops and markets prescription medicines and vaccines across immunology, rare diseases, neurology, oncology and other treatments. A broad international footprint is coordinated from Paris, while these activities are reported within a single Biopharma operating segment.
Specialty-care execution centers on expanding Dupixent across immune-mediated diseases, supported by biotechnology and rare-disease capabilities added through Genzyme. Vaccine growth and research productivity sit alongside launch execution as operating priorities.
Consumer health now sits outside operational control after the Opella separation, sharpening the focus on medicines and vaccines. Results depend on clinical development, regulatory approvals, manufacturing quality and product safety, while the Nasdaq-listed ADS represents half of one Paris-listed ordinary share.
Company facts
Categories
Key statistics
Year to date −7.1% · Average volume (30d) 2.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Morgan Stanley | Target | $52 | $49 | ||
| May 1, 2026 | Morgan Stanley | Downgrade | Overweight | Equal Weight | $56 | $52 |
| Apr 20, 2026 | BNP Paribas | Target | $50 | |||
| Apr 20, 2026 | Exane BNP Paribas | Downgrade | Outperform | Neutral | ||
| Feb 12, 2026 | B of A Securities | Downgrade | Buy | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $1.10 | $1.21 | +10.0% | $13.02B | $14.06B | +8.0% | −4.37% |
| Apr 23, 2026Q1 FY26 | $1.06 | $1.10 | +3.8% | $12.68B | $12.94B | +2.1% | −1.58% |
| Jan 29, 2026Q4 FY25 | $0.84 | $0.89 | +6.0% | $11.71B | $14.34B | +22.4% | +1.82% |
| Oct 24, 2025Q3 FY25 | $1.60 | $1.70 | +6.2% | $11.11B | $15.43B | +38.9% | −0.45% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $12.29B | $12.44B | $15.26B | $14.14B | $13.03B | $14.25B | |
| Gross profit | $8.94B | $8.97B | $11.31B | $9.94B | $9.39B | $10.76B | |
| Operating income | $2.59B | $1.71B | $4.20B | −$1.20B | $2.63B | $2.76B | |
| Net income | $2.17B | $4.57B | $3.25B | −$928.1M | $1.87B | $397.4M | |
| Diluted EPS | $0.88 | $1.85 | $1.32 | −$1.69 | $0.78 | $0.16 | |
| Gross margin | 72.8% | 72.1% | 74.1% | 70.3% | 72.1% | 75.5% | |
| Operating margin | 21.1% | 13.7% | 27.5% | -8.5% | 20.2% | 19.4% |
Fiscal years (4-quarter sums)FY21 $45.39B · FY22 $52.59B · FY23 $53.81B · FY24 $49.70B · FY25 $54.13B
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $7.36B · Total debt $27.32B · Total assets $149.54B · Shareholders' equity $80.19B
Dividends
Raised for 3 straight years — most recently to $2.419 from $2.1953 in May 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| May 4, 2026 | May 4 | Jun 3 | $2.419 | raised from $2.1953 |
| May 9, 2025 | May 9 | Jun 12 | $2.1953 | raised from $2.0369 |
| May 9, 2024 | May 10 | Jun 6 | $2.0369 | raised from $1.903 |
| May 30, 2023 | May 31 | Jun 23 | $1.903 | raised from $1.747 |
| May 26, 2022 | May 27 | Jun 27 | $0.297 | special dividend |
| May 4, 2022 | May 5 | May 31 | $1.747 |
Ownership
Shares outstanding 2.40B · Float 2.17B · 90.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 72.13M | 5.80% | 13G | Apr 23, 2025 |
| Amundi | 61.51M | 5.04% | 13G | Apr 10, 2026 |
| Dodge & Cox | 28.09M | 1.17% | 13F | Aug 13, 2026 |
| Morgan Stanley | 10.70M | 0.45% | 13F | Aug 13, 2026 |
| Fisher Asset Management, LLC | 10.63M | 0.44% | 13F | Aug 4, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- GSK (ADR)
Competes across vaccines and respiratory biologics
- AbbVie
Direct rival to Dupixent in systemic atopic dermatitis
- AstraZeneca (ADR)
UK biopharma rival in severe-asthma biologics
- Merck
Direct challenger to Beyfortus in infant RSV prevention
- Eli Lilly
US rival in atopic-dermatitis biologics and basal insulin
- Pfizer
Competes in infant RSV prevention and hemophilia prophylaxis
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| GSK (ADR) | $50.57 | −0.51% | $101.82B | 15.8 | 9.2 | 2.2 | +2.7% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 38.2 | 16.0 | 4.8 | +5.7% |